News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: Antidote For Rapid Reversal Of Pradaxa® (Dabigatran Etexilate) Progresses Into Next Stage Of Clinical Investigation With Study In Patients


5/22/2014 12:11:02 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Boehringer Ingelheim today announces the next step in the clinical development of idarucizumab*, the investigational antidote for rapid reversal of dabigatran-induced anticoagulation. The specific antidote has already demonstrated immediate, complete and sustained reversal of the anticoagulant effect of dabigatran in healthy volunteers.2 Now the potential antidote will be investigated in the clinical setting in patients taking Pradaxa® (dabigatran etexilate).1 This is the first time that an antidote under development for a novel oral anticoagulant is investigated in a study in patients.1

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES